fbpx Skip to main content

MONDAY, Oct. 19, 2020 (HealthDay News) — Neurologic disorders are not uncommon in hospitalized COVID-19 patients, according to a study published online Oct. 5 in Neurology.

Jennifer A. Frontera, M.D., from the New York University Grossman School of Medicine in New York City, and colleagues prospectively followed hospitalized severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-positive patients to assess new neurologic disorders and hospital outcomes. The analysis included 4,491 COVID-19 patients hospitalized between March 10, 2020, and May 20, 2020.

The researchers found that 13.5 percent of patients developed a new neurologic disorder in a median of two days from COVID-19 symptom onset, including toxic/metabolic encephalopathy (6.8 percent), seizure (1.6 percent), stroke (1.9 percent), and hypoxic/ischemic injury (1.4 percent). There were no reported cases of meningitis/encephalitis or myelopathy/myelitis related to SARS-CoV-2 infection. Neurologic disorders were more frequent among patients who were older, male, White, hypertensive, diabetic, and intubated and who had higher sequential organ failure assessment (SOFA) scores. When adjusting for age, sex, SOFA scores, intubation, medical history, medical complications, medications, and comfort care status, there was an increased risk for in-hospital mortality among COVID-19 patients with neurologic disorders (hazard ratio, 1.38), as well as a decreased likelihood of discharge home (hazard ratio, 0.72).

“The neurological complications seen in COVID-19 are predominately the secondary effects of being severely ill and suffering from low oxygen levels in the body for prolonged periods of time,” Frontera said in a statement.

Abstract/Full Text (subscription or payment may be required)

You May Also Like::  Environmental Stressors: Their Structural Nature and Impact on Cognitive Disorders

“Keeping up with the indications and adverse reactions to immune checkpoint inhibitors can be a full-time job. Cutaneous side effects occur in up to 45% of patients treated with ipilimumab and 34% of patients treated with nivolumab and pembrolizumab.” https://bit.ly/3FGtxtd

.@spfnomt: This month’s #DermWorld article “Estate planning 101” is especially important for young physicians to read. The long, all-consuming years between adolescence and physicianhood can become a blur...https://bit.ly/3FxOtCv

That’s a wrap #AAD2023! 5 days of soaking up knowledge from dermatologists on topics such as hidradenitis, melasma, & dietary triggers of common dermatoses.

I LOVED the #womenshealth focused sessions on vulvar dermatoses and pregnancy medication safety.


New approach uses microbiome to treat skin disease by repairing the injured microbiome that allowed inflammation to flare up in the first place, rather than reducing the inflammation after the fact. https://bit.ly/3Jt6H9v

Load More